peptides for sexual performance: Frequently asked questions

Verify dosing consistency and injection timing first. Ipamorelin and CJC-1295 combinations require subcutaneous administration at consistent intervals (typically evening before bed to align with natural GH pulse patterns) for 8–12 weeks before IGF-1 levels plateau. If compliance has been consistent, consider baseline IGF-1 testing: individuals with already-normal IGF-1 levels (180–250 ng/mL for adult males) may not experience further elevation or downstream vascular benefits. The sexual performance effects of GH secretagogues are indirect and secondary to metabolic optimization. If vascular function was not the limiting factor in baseline sexual performance, IGF-1 elevation will not address it.

Discard the vial and start over with a new lyophilized unit. Incorrect reconstitution. Using sterile water instead of bacteriostatic water, wrong dilution ratios, or injecting air into the vial during mixing. Creates contamination risk or unstable peptide solutions that degrade within hours. PT-141 is a cyclic heptapeptide with a disulfide bridge between cysteine residues. Mechanical agitation during mixing or exposure to non-bacteriostatic diluents disrupts this structure. The resulting solution may be microbiologically unsafe (sterile water lacks preservatives and supports bacterial growth once opened) or pharmacologically inert (aggregated peptide cannot bind melanocortin receptors). There is no salvage protocol once contamination or aggregation has occurred.

Use an insulin travel cooler with phase-change gel packs rated for 2–8°C maintenance. Brands like FRIO use evaporative cooling and maintain temperature for 36–48 hours without ice or electricity. Lyophilized (unmixed) peptides tolerate short-term ambient temperature (up to 25°C for 48 hours) but reconstituted solutions require continuous refrigeration. A single 6-hour temperature excursion to room temperature may not fully denature PT-141 or ipamorelin, but repeated excursions compound degradation. There is no at-home method to verify potency loss. If refrigeration is unavailable for more than 12 hours during travel, the conservative approach is to discard the reconstituted vial and reconstitute a fresh unit upon arrival.

Kisspeptin's gonadotropin response depends on baseline hypothalamic-pituitary function. Men with primary hypogonadism (testicular failure, elevated baseline LH) will not respond because the testes cannot produce more testosterone regardless of LH stimulation. If baseline LH is already high (>9 mIU/mL), kisspeptin's mechanism cannot compensate. The compound works only in central (hypothalamic) hypogonadism where GnRH pulsatility is impaired but testicular function is intact.

PT-141 and Selank can be used concurrently with sildenafil or tadalafil without pharmacokinetic interaction. They operate through different receptor systems (melanocortin and GABA vs phosphodiesterase inhibition). Combining PT-141 with a PDE5 inhibitor addresses both central arousal suppression and peripheral vascular capacity, which is useful when performance anxiety coexists with mild organic ED. Start each compound separately to assess individual response before combining. Oxytocin paired with PDE5 inhibitors has no documented contraindication, but dosing both on the same day requires timing: take the PDE5 inhibitor first (60–90 minutes before), then oxytocin intranasal 15–30 minutes before activity to align peak effects.

Reassess peptide-dysfunction alignment. PT-141 works by restoring melanocortin signaling in the CNS. If your dysfunction is primarily vascular (weak erections despite intact desire), PT-141 won't address the root mechanism. The second consideration is dosing frequency: on-demand dosing produces inconsistent plasma levels and unpredictable clinical response. Switch to a fixed schedule (2–3 injections weekly, same days and times) to maintain steady melanocortin receptor occupancy. If arousal and desire haven't improved by week six on a consistent schedule, the dysfunction likely isn't melanocortin-mediated. Vascular or hormonal pathways are more plausible.

Nausea and facial flushing are documented adverse effects of melanocortin receptor activation. They occur in 20–30% of users during the first two weeks and typically resolve with continued dosing as receptor desensitization occurs. Mitigation strategies: reduce the initial dose to 1.0 mg for the first three injections, then titrate to 1.75 mg once tolerance develops. Inject on a full stomach rather than fasting. Food doesn't significantly impair PT-141 absorption but does reduce nausea severity. If symptoms persist beyond two weeks at the standard dose, discontinue and consider alternative peptides.

If total testosterone is below 300 ng/dL, peptides alone rarely produce meaningful clinical improvement. Growth hormone secretagogues can modestly increase endogenous testosterone production (10–15% increases are documented), but this won't correct frank hypogonadism. The evidence-based approach: if baseline testosterone is 250–350 ng/dL, try ipamorelin or MK 677 for eight weeks and retest. If free testosterone rises above 10 ng/dL and symptoms improve, continue the protocol. If baseline testosterone is below 250 ng/dL, direct testosterone replacement is indicated. Peptides can be added afterward to optimize nitric oxide and vascular function.

Reduce the dose to 1.0–1.25mg and administer 60–90 minutes before activity instead of 45 minutes. Nausea and transient flushing are melanocortin receptor-mediated side effects that occur in approximately 40% of users at the 1.75mg dose but resolve within 60–90 minutes. Starting at a lower dose allows receptor tolerance to develop, reducing side effect intensity over 2–3 uses. Taking the peptide on an empty stomach compounds nausea. A small meal 30 minutes prior mitigates this. If symptoms persist beyond three administrations at reduced dose, PT-141 may not be well-tolerated for you.

Reduce the dose to 1.0–1.25mg instead of the standard 1.75mg and administer it 60–90 minutes before anticipated activity rather than 45 minutes. Slower absorption reduces peak plasma concentration spikes that trigger nausea. Taking the injection with a small amount of food (50–100 calories) further blunts the gastrointestinal response without meaningfully reducing efficacy. Clinical trial data showed nausea incidence dropped from 40% to under 20% when participants used the lower dose range.

MC1R activation is dose-dependent and cumulative. Darkening occurs because melanotan-II has 10- to 15-fold higher affinity for MC1R than PT-141. Switching to PT-141 eliminates the tanning effect within two to three weeks as melanin synthesis normalises. The darkening is reversible but can persist for months if MT-II use continues. There is no way to selectively block MC1R while preserving MC4R activation with melanotan-II. The compound's lack of receptor selectivity is a structural limitation.

Increase the intranasal dose to 32–40 IU and ensure proper nasal spray technique. Tilting the head back and spraying into the upper nasal cavity (not the throat) is critical for absorption. Intranasal oxytocin's bioavailability is highly variable (10–40%) depending on mucosal contact time and administration angle. Additionally, oxytocin's anxiolytic effect is context-dependent: it reduces amygdala activation specifically in social-threat contexts (fear of judgment, rejection) but has minimal effect on non-social stressors (financial anxiety, work deadlines). If your performance anxiety stems from generalised stress rather than partner-specific fears, Selank may be a better match.